Omicron infects 70 times faster but may cause less severe disease: Study

The yet-to-be peer-reviewed study provides the first information on how the novel variant of concern infects human respiratory tract

A health worker takes a swab at a Covid-19 testing site in Uttar Pradesh, on May 4.(Photo: Bloomberg)
Press Trust of India Beijing
2 min read Last Updated : Dec 16 2021 | 1:40 PM IST

The Omicron variant of coronavirus infects and multiplies 70 times faster than Delta and the original COVID-19 strain, but the severity of illness is likely to be much lower, according to a study.

The yet-to-be peer-reviewed study provides the first information on how the novel variant of concern infects human respiratory tract.

The researchers from University of Hong Kong found that Omicron infects and multiplies 70 times faster than the Delta variant and original SARS-CoV-2 in human bronchus, which may explain why it may transmit faster between humans than previous variants.

A bronchus is a passage or airway in the lower respiratory tract that conducts air into the lungs.

The study also showed that the Omicron infection in the lung is significantly lower than the original SARS-CoV-2, which may indicate lower disease severity.

The researchers used ex-vivo cultures of the respiratory tract to understand why Omicron may differ in transmission and disease severity from other SARS-CoV-2 variants.

This method uses lung tissue removed for treatment of the lung, which is normally discarded, for investigating viral diseases of the respiratory tract.

Michael Chan Chi-wai, Associate Professor at University of Hong Kong, and his team successfully isolated Omicron and compared infection from the variant with the original SARS-CoV-2 from 2020, and the Delta variant.

The team found that the Omicron replicates faster than the original SARS-CoV-2 virus and Delta variant in the human bronchus.

At 24 hours after infection, the Omicron variant replicated around 70 times higher than the Delta variant and the original SARS-CoV-2 virus, the researchers said.

Omicron replicated less efficiently -- over 10 times lower -- in the human lung tissue than the original SARS-CoV-2 virus, which may suggest lower severity of disease, they said.

"It is important to note that the severity of disease in humans is not determined only by virus replication but also by the host immune response to the infection, which may lead to dysregulation of the innate immune system," Chan said in a statement.

"It is also noted that by infecting many more people, a very infectious virus may cause more severe disease and death even though the virus itself may be less pathogenic," he explained.

Taken together with the recent studies that showed Omicron can partially escape immunity from vaccines and past infection, the overall threat from the variant is likely to be very significant, the researchers added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Dec 16 2021 | 1:40 PM IST

Next Story